PRESS RELEASE published on 12/09/2025 at 13:04, 3 months 17 days ago Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada Formycon AG and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada. Agreement includes milestone payments, development progress, and upcoming data release Formycon AG Biosimilar Keytruda Zydus Exclusive Licensing
BRIEF published on 12/04/2025 at 06:35, 3 months 22 days ago Formycon et MS Pharma collaborent pour le biosimilaire de Keytruda® au Moyen-Orient et en Afrique du Nord MS Pharma Keytruda® FYB206 Accord Sur Les Biosimilaires Marché MENA Partenariat Formycon
BRIEF published on 12/04/2025 at 06:35, 3 months 22 days ago Formycon and MS Pharma Collaborate for Keytruda® Biosimilar in MENA MS Pharma Biosimilar Agreement Keytruda® FYB206 MENA Market Formycon Partnership
PRESS RELEASE published on 12/04/2025 at 06:30, 3 months 22 days ago Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region Formycon AG and MS Pharma enter exclusive partnership to commercialize Keytruda biosimilar FYB206 in MENA region, aiming to enhance cancer drug access MENA Region MS Pharma Biosimilar Formycon Keytruda
BRIEF published on 11/24/2025 at 06:35, 4 months 2 days ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:35, 4 months 2 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 4 months 2 days ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 4 months 6 days ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
BRIEF published on 11/20/2025 at 17:05, 4 months 6 days ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
PRESS RELEASE published on 11/20/2025 at 17:00, 4 months 6 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
Published on 03/26/2026 at 23:00, 28 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 1 hour 23 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 1 hour 28 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 1 hour 28 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 2 hours 28 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 2 hours 39 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 4 hours 7 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 4 hours 18 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 4 hours 18 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 5 hours 11 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 5 hours 11 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 5 hours 28 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 5 hours 28 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
